Last 48 quarters of trend data · Healthcare · Medical - Instruments & Supplies
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
EV/EBITDA has expanded 32.6% YoY to 16.9x, reflecting rising market expectations or slowing EBITDA growth.
| Metric | TTM | Q4 '26 | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 36.18 | — | 21.13 | 14.87 | 26.36 | 13.58 | 26.21 | 30.23 | 27.95 | 53.34 | 35.05 | 46.66 | 26.61 |
| — | — | -19.4% | -50.8% | -5.7% | -74.5% | -25.2% | -35.2% | +5.0% | +47.0% | +14.1% | +61.3% | -39.9% | |
| P/S Ratio | 2.58 | 1.80 | 2.78 | 1.75 | 2.78 | 2.38 | 2.82 | 2.96 | 3.17 | 3.20 | 3.27 | 3.62 | 3.51 |
| — | -24.2% | -1.3% | -40.7% | -12.5% | -25.6% | -13.9% | -18.2% | -9.6% | -8.2% | -0.8% | +12.8% | +5.5% | |
| P/B Ratio | 4.41 | 3.14 | 4.14 | 2.70 | 4.04 | 3.83 | 4.33 | 4.65 | 4.71 | 4.57 | 4.66 | 5.15 | 5.06 |
| — | -18.1% | -4.5% | -41.9% | -14.2% | -16.2% | -7.1% | -9.7% | -6.8% | -11.8% | -10.2% | -1.6% | +11.9% | |
| P/FCF | 13.23 | 11.72 | 10.81 | 5.40 | 65.40 | 7.79 | 27.88 | 25.95 | — | 20.17 | — | 15.46 | 115.97 |
| — | +50.5% | -61.2% | -79.2% | — | -61.4% | — | +67.9% | — | +28.8% | — | -17.3% | — | |
| EV / EBITDA | 11.15 | 16.90 | 11.95 | 8.44 | 13.62 | 12.75 | 13.72 | 15.49 | 18.67 | 25.60 | 18.26 | 21.45 | 15.84 |
| — | +32.6% | -12.9% | -45.5% | -27.1% | -50.2% | -24.8% | -27.8% | +17.9% | +9.8% | +6.8% | +37.7% | -17.0% | |
| EV / EBIT | 18.33 | 16.90 | 16.65 | 11.98 | 17.33 | 19.73 | 18.27 | 20.98 | 25.23 | 25.39 | 21.51 | 29.42 | 22.60 |
| — | -14.4% | -8.9% | -42.9% | -31.3% | -22.3% | -15.1% | -28.7% | +11.6% | -0.5% | -18.5% | +26.1% | -31.1% |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Haemonetics Corporation's operating margin was 14.9% in Q4 2026, down 5.7 pp QoQ and down 0.7 pp YoY. The trailing four-quarter average of 18.2% exceeds the current quarter, suggesting the latest result may reflect seasonal weakness or a one-off headwind. Gross margin expanded 4.0% YoY, indicating pricing power or improving input costs.
| Metric | TTM | Q4 '26 | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 55.7% | 57.2% | 56.5% | 56.0% | 59.7% | 55.0% | 57.4% | 55.3% | 53.3% | 55.0% | 55.0% | 53.6% | 53.8% |
| — | +4.0% | -1.6% | +1.3% | +11.9% | -0.0% | +4.3% | +3.2% | -0.9% | +2.0% | +5.8% | +1.0% | -1.0% | |
| Operating Margin | 18.1% | 14.9% | 20.5% | 20.6% | 16.8% | 15.6% | 16.9% | 15.0% | 11.8% | 8.7% | 13.7% | 11.1% | 17.2% |
| — | -4.6% | +21.2% | +37.4% | +41.7% | +78.5% | +23.9% | +34.9% | -31.4% | -24.7% | -3.5% | -29.4% | +46.5% | |
| Net Margin | 7.3% | -5.8% | 13.2% | 11.8% | 10.6% | 17.5% | 10.8% | 9.8% | 11.4% | 5.9% | 9.3% | 7.8% | 13.2% |
| — | -133.2% | +22.7% | +20.7% | -7.2% | +195.6% | +15.8% | +25.1% | -13.4% | -38.5% | -13.9% | -29.8% | +73.4% |
| Metric | TTM | Q4 '26 | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 12.0% | -2.4% | 5.1% | 4.5% | 4.0% | 6.7% | 4.2% | 3.8% | 4.1% | 2.1% | 3.4% | 2.8% | 4.9% |
| — | -135.2% | +21.0% | +17.8% | -2.9% | +213.6% | +23.5% | +33.8% | -15.7% | -41.9% | -22.3% | -36.0% | +86.5% | |
| ROA | 4.0% | -0.8% | 1.8% | 1.6% | 1.4% | 2.3% | 1.5% | 1.3% | 1.6% | 0.9% | 1.5% | 1.3% | 2.1% |
| — | -135.4% | +22.3% | +18.1% | -14.5% | +151.2% | -0.0% | +6.5% | -23.1% | -39.9% | -15.7% | -30.4% | +95.0% | |
| ROIC | 10.3% | 2.2% | 2.9% | 2.8% | 2.3% | 2.2% | 2.4% | 2.2% | 1.8% | 1.4% | 2.4% | 2.0% | 3.0% |
| — | +0.0% | +20.0% | +30.0% | +28.7% | +55.4% | +3.9% | +8.1% | -41.9% | -30.7% | -4.7% | -25.0% | +71.3% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
Haemonetics Corporation's Debt/EBITDA ratio is 23.8x, up from 12.6x last quarter — elevated, raising questions about debt serviceability. The current ratio has improved 82.7% YoY to 2.95x, strengthening the short-term liquidity position.
| Metric | TTM | Q4 '26 | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 1.54 | 1.54 | 1.34 | 1.44 | 1.39 | 1.49 | 1.35 | 1.39 | 1.35 | 0.84 | 0.92 | 0.85 | 0.88 |
| — | +3.1% | -0.5% | +3.5% | +2.7% | +77.3% | +46.3% | +63.4% | +52.8% | -10.1% | -6.6% | -24.0% | -11.5% | |
| Debt / EBITDA | 3.08 | 23.80 | 12.63 | 12.82 | 14.82 | 15.37 | 13.91 | 15.14 | 17.76 | 16.49 | 12.52 | 13.04 | 9.99 |
| — | +54.8% | -9.2% | -15.3% | -16.5% | -6.8% | +11.1% | +16.1% | +77.7% | +9.0% | +9.2% | +12.4% | -31.4% | |
| Current Ratio | 2.95 | 2.95 | 1.75 | 1.64 | 1.72 | 1.62 | 3.97 | 3.49 | 3.76 | 2.56 | 2.92 | 3.28 | 3.38 |
| — | +82.7% | -56.0% | -53.0% | -54.3% | -36.8% | +35.9% | +6.5% | +11.2% | -16.3% | -6.1% | +20.0% | -11.2% | |
| Quick Ratio | 1.87 | 1.87 | 1.15 | 1.03 | 1.04 | 0.99 | 2.55 | 2.09 | 2.33 | 1.50 | 1.76 | 2.19 | 2.16 |
| — | +89.7% | -54.8% | -50.9% | -55.3% | -34.5% | +44.9% | -4.6% | +7.5% | -25.8% | -11.3% | +24.8% | -4.8% | |
| Interest Coverage | 8.41 | 9.57 | 8.56 | 9.33 | 15.94 | — | 7.26 | 8.55 | — | 7.57 | 30.27 | 17.25 | 25.93 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying HAE stock.
Haemonetics Corporation's current P/E is 36.2x. The average P/E over the last 3 quarters is 20.8x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Haemonetics Corporation's current operating margin is 18.1%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Haemonetics Corporation's business trajectory between earnings reports.